‘RCC treatment should reflect international guidelines’
By Son, Hyung-Min | translator Kim, Jung-Ju
24.01.08 16:10:38
가나다라
0
In-Keun Park, Professor of Oncology, Seoul Asan Medical Center
Introduction of first-line Immuno-oncology options improve survival...but options for later-line therapies remain limited
Cabometyx demonstrated efficacy but is non-reimbursed…”Latest guidelines need to be applied in Korea as well"
▲In-Keun Park, Professor of Oncology at Seoul Asan Medical Center
The treatment paradigm for renal cell carcinoma has been changing with the emergence of immuno-oncology drugs, but the latest practice guidelines for the disease are not being reflected in practice in Korea.In-Keun Park, Professor of Oncology at Seoul Asan Medical Center stressed how treatment options for patients with recurrent renal cell carcinoma are limited.
In the first-line treatment of renal cell carcinoma, immuno-oncology drugs have been approved and have been successful in improving survival rates. However, treatment options for recurrent patients remain limited.
As renal cell carcinoma is often diagnosed at an advanced stage, it has a poor prognosis and a high r
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)